Daniel O’Day, Gilead Sciences’ CEO, has released an open letter on Saturday. As per the notice, the pharmaceutical will extend access to its untried drug remdesivir to contain seriously ill coronavirus patients. Before this, the use of unproven and experimental COVID-19 medication was prohibited around a week ago. But now, because of increasing demand, the drug has become once again available to doctors beneath extended access program. Recently, President Donald Trump has called remdesivir, the medication, as a promising drug to treat COVID-19. Well, there is no information available yet to reveal whether the drug is effective and safe at curing new coronavirus. The pharmaceutical has had developed remdesivir as a probable medication for Marburg and Ebola virus.
O’Day has noted in the announcement that his company is once again making the drug available other than ongoing trials. Currently, six trials are examining whether remdesivir is efficient enough to treat COVID-19. Even the World Health Organization is involved in the tests. By announcing to offer expanded access, the company has stepped up from the compassionate use scheme. O’Day said the expanded access program would enable the pharmaceutical to support and handle a large number of applications. As per the letter, pregnant women and children can also avail the compassionate use scheme. Notably, the company is looking forward to offering remdesivir to over 1,000 patients under the program. O’Day noted it is essential to establish the efficiency and safety of this new medicine, before deploying it for universal use.
The Gilead CEO also said if the medication gets approval, they will function to make sure accessibility so that the drug would become available for patients with the greatest requirement. For now, the distribution of remdesivir will take place under a government-approved expanded access program. To date, no trials have offered information that would pinpoint the impact of the medication on COVID-19 patients. Meanwhile, O’Day noted Gilead, based in Foster City, California, aims to have at least primary data on its functioning in the upcoming weeks. Above all, Remdesivir can only be monitored by intravenous infusion for the period between 30-120 minutes. Most importantly, the drug is not available as a vaccine or a pill.